- Molecular NameValaciclovir
- Synonymvalaciclovir; Valaciclovir Hcl; Valaciclovir Hydrochloride; Valacyclover Hydrochloric; Valacyclover Hydrochloride; Valacyclovir; Valacyclovir Hydrochloride
- Weight324.341
- Drugbank_IDDB00577
- ACS_NO124832-26-4
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-0.92
- pka1.90, 7.47, 9.43
- LogD (pH=7, predicted)-1.63
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.53
- LogSw (predicted, AB/LogsW2.0)3.66
- Sw (mg/ml) (predicted, ACD/Labs)1.47
- No.of HBond Donors5
- No.of HBond Acceptors10
- No.of Rotatable Bonds8
- TPSA146.85
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiviral drug used in the management of herpes simplex and herpes zoster (shingles).
- Absorption_valueN/A
- Absorption (description)After oral administration, valaciclovir hydrochloride is rapidly absorbed from the gastrointestinal tract.
- Caco_2N/A
- Bioavailability0.0
- Protein binding15.7
- Volume of distribution (VD)Has not been calculated, as the drug has not been administered intravenously and the elimination rate constant has not been accurately measured. Aciclovir is 50 L in a typical adult.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmValaciclovir is rapidly and almost entirely (~99%) converted to the active compound, acyclovir, and L-valine by first-pass intestinal and hepatic metabolism by enzymatic hydrolysis. Neither valaciclovir nor acyclovir is metabolized by cytochrome P450 enzymes.
- Half life3 h as aciclovir which may be increased to 14 h in patients with end stage renal disease.
- ExcretionRenal 40–50% (aciclovir), faecal 47% (aciclovir)
- Urinary Excretion<1
- CleranceN/A
- ToxicityAdverse effects of overexposure might include headache and nausea.
- LD50 (rat)N/A
- LD50 (mouse)N/A